# Revolution Medicines, Inc. (RVMD) FY2025 Annual Balance Sheet

- Company: Revolution Medicines, Inc. (RVMD)
- Period: As of 2025-12-31
- Filing: FY2025 10-K, filed 2026-02-25, accession number 0001193125-26-071563
- Page: https://plicit.ai/financials/rvmd/fy2025-annual-balance-sheet
- Chart image: https://plicit.ai/charts/rvmd-fy2025-annual-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2025-12-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 2,354,508,000 US dollars
- **Current assets**: 2,075,037,000 US dollars
- **Non-current assets**: 279,471,000 US dollars
- **Liabilities**: 723,211,000 US dollars
- **Current liabilities**: 290,424,000 US dollars
- **Non-current liabilities**: 432,787,000 US dollars
- **Equity**: 1,631,297,000 US dollars
- **Marketable securities**: 1,641,934,000 US dollars
- **Cash and cash equivalents**: 383,745,000 US dollars
- **Prepaid expenses and other current assets**: 49,358,000 US dollars
- **Operating lease right-of-use asset**: 132,084,000 US dollars
- **Intangible assets, net**: 55,800,000 US dollars
- **Property and equipment, net**: 33,194,000 US dollars
- **Long-term deposits**: 24,148,000 US dollars
- **Other noncurrent assets**: 14,779,000 US dollars
- **Goodwill**: 14,608,000 US dollars
- **Restricted cash**: 4,858,000 US dollars
- **Accrued expenses and other current liabilities**: 209,340,000 US dollars
- **Accounts payable**: 64,616,000 US dollars
- **Operating lease liability, current**: 16,468,000 US dollars
- **Liability related to the sale of future royalties**: 268,446,000 US dollars
- **Operating lease liability, noncurrent**: 142,234,000 US dollars
- **Warrant liability**: 18,546,000 US dollars
- **Deferred tax liability**: 2,353,000 US dollars
- **Other noncurrent liabilities**: 1,208,000 US dollars
- **Additional paid-in capital**: 4,497,143,000 US dollars
- **Accumulated other comprehensive income**: 3,237,000 US dollars
- **Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 197,001,401 and 185,896,625 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively**: 19,000 US dollars
- **Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; none issued and outstanding at December 31, 2025 and December 31, 2024, respectively**: 0 US dollars
- **Accumulated deficit**: negative 2,869,102,000 US dollars
- **Gross equity (calculated)**: 4,500,399,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.